Skip to content

Author

Adam Simmons

We have 2 of 6 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Oct 2026

Phase 3 randomized trial of latozinemab in frontotemporal dementia due to GRN mutations

Abstract INTRODUCTION Heterozygous progranulin gene mutations causing frontotemporal dementia (FTD‐GRN) are associated with deficiency in progranulin (PGRN). Latozinemab is a human monoclonal immunoglobulin G1 (IgG1) antibody designed to elevate PGRN levels in people with heterozygous loss‐of‐function (LOF) GRN mutatio...

Adam Simmons, B. Boeve, I. Le Ber et al. · 0 citations
Review Aug 2026

TDP-43-Associated Neurodegenerative Disease Conceptualization and Integrated Staging: A Review.

A pathobiological definition of disease is proposed to provide a road map for developing biomarkers that accurately reflect the underlying pathobiology of disease and for advancing therapeutic candidates that effectively target fundamental disease mechanisms.

M. Benatar, SJ Barmada, Gregory A. Jicha et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.